Company intelligence / Profile preview

Cyclomics

Amsterdam, Netherlands

Ownership: Private
Development stage: Other

Overview

Cyclomics has validated its CyclomicsSeq technology in clinical proof-of-concept projects, enabling highly sensitive early cancer and recurrence detection via liquid biopsy. The CyclomicsSeq TP53 in vitro diagnostic kit is available and successfully identifies cancer-associated TP53 mutations from blood with near single-molecule resolution[2][4].

Therapeutic areas: Oncology
Modalities: DeviceDiagnostic assaySequencing technology
Industry: Molecular Diagnostics

Partnerships

Oxford NanoporeNvidiaGEDiCube (now RenovaroCube)

Beyond the preview

Go deeper on Cyclomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclomics.

Explore the full profile